RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

Overview

About this study

RESTORE tests whether Augmented-FLS, where patients are contacted by a patient navigator (serving as the liaison) and referred to a bone health provider, is better than Enhanced Usual Care, which includes patient and PCP education and activation. We also aim to determine the influence of age, race, ethnicity, sex, poverty level, geographic region, and timing of entry into the trial after a fracture on the effectiveness of the two strategies.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Age 50 years and older (no upper age limit)
* Sustained a primary fragility fracture (hip/femur/pelvis, clinical spine, humerus, wrist/forearm) in the last 6 months
* Participant must self-identify a regular primary care provider (PCP)

Exclusion Criteria:

* Exposure to the following medications in the prior 12 months
* Actonel or Atelvia (risedronate)
* Fosamax or Binosto (alendronate)
* Reclast, Zometa, or Aclasta (zoledronic acid, zoledronate)
* Boniva or Bondronat (ibandronate)
* Aredia (pamidronate)
* Prolia (denosumab)
* Evenity (romozosumab)
* Tymlos (abaloparatide)
* Forteo (teriparatide)
* Natpara (parathyroid hormone)
* Evista (raloxifene)
* Miacalcin (calcitonin)
* Diagnosis of the following medical conditions

* CKD stage 4 and above
* Paget's disease
* Multiple myeloma
* Osteomalacia
* Hyperparathyroidism
* History of hyperthyroidism (stable on antithyroid therapy is allowed)
* History of hypothyroidism (stable on thyroid replacement therapy is allowed)
* Addison's disease
* Adrenal insufficiency
* Enrolled hospice care
* Solid organ transplant
* Bone marrow transplant
* Active malignancy undergoing treatment, hospice

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/5/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Krupa Doshi, M.D.

Contact us for the latest status

Contact information:

Krupa Doshi M.D.

Doshi.Krupa@mayo.edu

More information

Publications

Publications are currently not available